Lucemyra, a selective alpha 2-adrenergic receptor agonist, works by reducing the release of norepinephrine and decreasing sympathetic tone.
If approved, Lucemyra will be the first non-opioid medication indicated to mitigate opioid withdrawal symptoms.
The proposal addresses inappropriate ICD-10-CM coding options for withdrawal from opioids, sedatives, or stimulants.
US WorldMeds announced that the Food and Drug Administration has accepted for Priority Review the New Drug Application for lofexidine to manage the symptoms associated with opioid withdrawal and to facilitate completion of opioid discontinuation treatment.
The extended-release formulation of tramadol was shown to be as effective as buprenorphine and more effective than clonidine for treating symptoms of opioid withdrawal.
The DEA's plan to list kratom as a Schedule I controlled substance would make researching the possible opioid substitute much more difficult.
Clinical Pain Advisor Articles
- Opioid Use in Chronic Low Back Pain: A Population Study
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- FDA Approves Aimovig for Migraine Prevention
- Stages of Low Back Pain Have Specific Sets of Clinical Indicators
- First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Interbrain Coupling During Handholding Associated With Analgesia, Empathy
- Opioid-Related Adverse Drug Events Associated With Worse Patient, Cost Outcomes
- Education Plus Exercise, Single Corticosteroid Injection Effective in Long Term for Gluteal Tendinopathy
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Naloxone Training Beneficial for PA Students
- Supervised Injection Sites Hailed as the Latest Strategy to Fight the Opioid Crisis